EyePoint Pharmaceuticals, Inc. announced the pricing of an underwritten public offering, expecting to raise approximately $150 million. The offering includes 11,000,000 shares of common stock and pre-funded warrants. Proceeds will support the development of DURAVYU™ for wet age-related macular degeneration and diabetic macular edema. The company has granted underwriters an option to purchase additional shares. EyePoint is committed to developing innovative therapeutics for serious retinal diseases. J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book running managers for the offering. EyePoint’s lead product candidate, DURAVYU™, is currently in Phase 3 pivotal trials for wet AMD.

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of patients with serious retinal diseases. DURAVYU™ combines vorolanib and innovative bioerodible Durasert E™ technology. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts. Vorolanib is licensed exclusively to EyePoint for the treatment of ophthalmic diseases. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. Forward-looking statements in this press release address EyePoint’s clinical development plans and uncertainties.

Read more at GlobeNewswire: EyePoint Announces Pricing of Public Offering